Abstract
HMB-45 (melanocytic cell-specific monoclonal antibody) immunoreactivity was investigated in 10 cases of angiomyolipoma (AML) (1 with massive regional lymph node involvement) of the kidney and detected in all of them. No HMB-45 immunoreactivity was found in other tumors of the region which can occasionally be confused with AML, such as renal cell carcinoma, Wilms' tumor, and retroperitoneal sarcoma (leiomyosarcoma and liposarcoma). These findings indicate that HMB-45 is not a melanocyte-restricted marker and suggest that its expression might be useful in distinguishing AML from other tumors of the kidney and retroperitoneum.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / immunology*
-
Biomarkers, Tumor / analysis*
-
Carcinoma, Renal Cell / diagnosis
-
Carcinoma, Renal Cell / immunology
-
Diagnosis, Differential
-
Hemangioma / diagnosis
-
Hemangioma / immunology*
-
Humans
-
Immunohistochemistry
-
Kidney Neoplasms / diagnosis
-
Kidney Neoplasms / immunology*
-
Lipoma / diagnosis
-
Lipoma / immunology*
-
Melanocytes / immunology*
-
Retroperitoneal Neoplasms / diagnosis
-
Retroperitoneal Neoplasms / immunology
-
Sarcoma / diagnosis
-
Sarcoma / immunology
-
Wilms Tumor / diagnosis
-
Wilms Tumor / immunology
Substances
-
Antibodies, Monoclonal
-
Biomarkers, Tumor